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Abstract
Introduction Studies in xenograft models and experimental
models of metastasis have implicated several β3 integrin-
expressing cell populations, including endothelium, platelets
and osteoclasts, in breast tumor progression. Since orthotopic
human xenograft models of breast cancer are poorly metastatic
to bone and experimental models bypass the formation of a
primary tumor, however, the precise contribution of tumor-
specific αvβ3 to the spontaneous metastasis of breast tumors
from the mammary gland to bone remains unclear.
Methods We used a syngeneic orthotopic model of
spontaneous breast cancer metastasis to test whether
exogenous expression of αvβ3 in a mammary carcinoma line
(66cl4) that metastasizes to the lung, but not to bone, was
sufficient to promote its spontaneous metastasis to bone from
the mammary gland. The tumor burden in the spine and the lung
following inoculation of αvβ3-expressing 66cl4 (66cl4beta3)
tumor cells or control 66cl4pBabe into the mammary gland was
analyzed by real-time quantitative PCR. The ability of these cells
to grow and form osteolytic lesions in bone was determined by
histology and tartrate-resistant acid phosphatase staining of
bone sections following intratibial injection of tumor cells. The
adhesive, migratory and invasive properties of 66cl4pBabe and
66cl4beta3 cells were evaluated in standard in vitro assays.
Results The 66cl4beta3 tumors showed a 20-fold increase in
metastatic burden in the spine compared with 66cl4pBabe. A
similar trend in lung metastasis was observed. αvβ3 did not
increase the proliferation of 66cl4 cells in vitro or in the
mammary gland in vivo. Similarly, αvβ3 is not required for the
proliferation of 66cl4 cells in bone as both 66cl4pBabe and
66cl4beta3 proliferated to the same extent when injected
directly into the tibia. 66cl4beta3 tumor growth in the tibia,
however, increased osteoclast recruitment and bone resorption
compared with 66cl4 tumors. Moreover, αvβ3 increased 66cl4
tumor cell adhesion and αvβ3-dependent haptotactic migration
towards bone matrix proteins, as well as their chemotactic
response to bone-derived soluble factors in vitro.
Conclusion These results demonstrate for the first time that
tumor-specific αvβ3 contributes to spontaneous metastasis of
breast tumors to bone and suggest a critical role for this
receptor in mediating chemotactic and haptotactic migration
towards bone factors.
Introduction
Breast cancer affects one in ten women in developed nations.
The prognosis is favorable for women with clinically confined
tumors at the time of diagnosis, but mortality rates are greater
than 80% in cases where the tumor has metastasized to dis-
tant sites [1]. Metastasis to bone occurs frequently in
advanced breast cancer and is accompanied by debilitating
skeletal complications [2]. Current treatments are largely palli-
ative and new therapies that specifically prevent the spread of
breast cancer to bone are urgently required. Little is known,
however, about the molecular determinants that regulate hom-
ing of breast cancer cells to bone.
Integrins are dimeric adhesion receptors that mediate cellular
attachment to the extracellular matrix (ECM) or to adjacent
cells. Interaction of integrins with their substrates regulates
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various cellular functions associated with tumor development
and metastatic progression, including cell adhesion, migration,
invasion, proliferation and survival/anoikis [3]. The changes in
the integrin activation state and the alteration in the level of
expression of integrins or their ECM ligands have therefore
been extensively documented and are thought to contribute to
neoplastic progression [4-6].
Studies examining the expression of αvβ3 integrin in various
tumor tissues have been strongly suggestive of a potential role
for this receptor in tumor progression, particularly for invasive
tumors that preferentially metastasize to bone, such as breast
and prostate carcinomas [7,8]. β3-type integrins (αvβ3 and
αIIbβ3) are expressed in multiple cell types including invasive
tumor cells, osteoclasts, activated endothelial and smooth
muscle cells, platelets, megakaryocytes and macrophages [9].
Accordingly, the contribution of several of these β3-expressing
cell populations to tumor growth and metastatic progression
has been demonstrated in studies using specific inhibitors
and/or genetic ablation of β3 receptors in animal models [10-
15].
Consistent with enhanced endothelial expression of αvβ3
integrin in the tumor vasculature [10,11,16,17] and its role in
promoting primary tumor growth, small molecule antagonists
or function-blocking antibodies targeting β3 integrins exert
anti-tumor effects concomitant with decreased tumor vascu-
larization in melanoma, prostate cancer and breast cancer
xenograft models [11,12,18-20]. Interestingly, studies examin-
ing tumor growth in mice null for β3 integrin have yielded
results apparently at odds with the inhibitor data. In contrast to
the decreased tumor growth and angiogenesis observed upon
treatment with β3 inhibitors, these responses are enhanced in
β3-null mice [13,21]. To reconcile these studies, it was pro-
posed that αvβ3 may function as an angiogenic switch, pro-
moting vessel growth when ligated but triggering an apoptotic
response in αvβ3-expressing endothelial cells in the absence
of appropriate ligand. In β3-null mice the absence of endothe-
lial αvβ3 may remove apoptotic signals, allowing excessive
endothelial growth [21,22].
Some of the discrepancies between studies using β3 antago-
nists and genetic ablation of β3 may be attributed also in part
to the lack of receptor specificity for some of the inhibitors
used in vivo or to their direct effect on tumor cells, as previ-
ously suggested [22]. β3 inhibitors would presumably inhibit
both host populations and tumor cell populations expressing
these receptors, whereas β3 ablation would target only host
populations, including cells of the innate immune system,
which may exert either pro-tumor or anti-tumor effects and pro-
duce a net stimulatory effect on primary tumor growth [13].
While there is strong correlative evidence supporting the role
of tumor-specific αvβ3 expression in breast cancer progres-
sion [7,23,24], its precise contribution to primary tumor
growth and metastasis is still unclear. Human breast tumor
lines expressing αvβ3 are typically more metastatic in
xenograft models than those that do not express this receptor
[25]. From in vitro studies, a variety of functions likely to con-
tribute to tumor progression have been ascribed to αvβ3
expressed on tumor cells. In particular, αvβ3 mediates breast
tumor cell adhesion to vitronectin and other bone ECMs and
promotes their survival, migration and invasion on bone matrix
in vitro [25-29]. These processes can be inhibited by anti-
αvβ3 antibodies or antagonists [25,27,28,30]. In addition,
activated αvβ3 regulates protease maturation, is required for
breast tumor cell interaction with platelets [5,14,31] and con-
tributes to breast tumor cell adhesion to the subendothelial
matrix under dynamic blood flow conditions [32].
In vivo studies addressing specifically the role of tumor cell
αvβ3 on primary tumor growth are conflicting, however. Exog-
enous expression of wildtype or constitutively active αvβ3 in
transformed human astrocytes exerts suppressive effects on
intracranial growth of gliomas, giving rise to fewer and smaller
tumors [33]. Expression of αvβ3 in 21NT human mammary
carcinoma cells is insufficient alone to enhance their growth in
the mammary fat pad of nude mice [34], whereas the same
approach reduces subcutaneous growth of MCF-7 cells in
nude mice [35]. It is also probable that tumor αvβ3 may have
different roles at various stages of metastatic progression. In
fact, expression of activated αvβ3 in melanoma and breast
cancer cells enhances experimental metastasis to the lung fol-
lowing intravenous injection of tumor cells (which bypasses
the formation of a primary tumor) in immune-compromised
mice [14,36]. Enhanced metastasis of breast tumor cells was
postulated to be mediated through tumor-induced platelet
aggregation and arrest in capillaries as these processes are
inhibited by antibodies targeting specifically platelet αIIbβ3 or
human αvβ3 on tumor cells [14]. Whether these interactions
are required for spontaneous metastasis of breast tumors from
orthotopic sites remains unclear, however.
Vascular or oral administration of selective inhibitors of αvβ3
S247 and S137, respectively, was reported to significantly
reduce spontaneous metastasis of 435/HAL breast tumor
cells to the lung from the mammary gland in severe combined
immunodeficient mice [37]. Neither drug inhibited primary
tumor growth or platelet aggregation at the concentration
used, and thus the antimetastatic effects are unlikely to be
mediated through these processes. Similar evidence support-
ing the role of tumor-specific αvβ3 in bone metastasis has
been reported. Chinese hamster ovary cells or MDA-MB-231
variants overexpressing αvβ3 are more metastatic to bone
than their respective parental line when inoculated intrave-
nously [38]. Conversely, treatment of mice with the selective
αvβ3 inhibitor S247 dramatically reduces the incidence and
size of MDA-MB-435 osteolytic lesions whereas the specific
platelet aggregation inhibitor ML464 prevents B16 melanomaAvailable online http://breast-cancer-research.com/content/8/2/R20
Page 3 of 14
(page number not for citation purposes)
metastases to bone in the intracardiac experimental model
[15,39].
While informative, the lack of a primary tumor in experimental
models of bone metastasis makes it difficult to assess whether
tumor αvβ3 is required at the primary site, the metastatic site
or both sites for spontaneous metastasis from the mammary
gland to bone. Conversely, current xenograft models of breast
cancer metastasis are poorly metastatic to bone from the
orthotopic site and thus have not been used to investigate the
role of tumor αvβ3 in spontaneous breast cancer metastasis
to bone. To circumvent these problems, we have used a syn-
geneic orthotopic model of spontaneous breast cancer metas-
tasis developed in our laboratory [40,41] and asked whether
exogenous expression of αvβ3 integrin in 66cl4 mammary car-
cinoma cells that metastasize to the lung but not bone is suffi-
cient to promote their spontaneous metastasis from the
mammary gland to bone. The model allows the simultaneous
measurement of the impact of αvβ3 expression on primary
tumor growth and on the metastatic burden in bone in immu-
nocompetent Balb/c mice. Our results indicate that tumor
expression of αvβ3 does not alter the proliferation of 66cl4
cells in vitro or in the mammary gland, and nor is it required for
their growth in bone. The expression of αvβ3 in these cells,
however, is sufficient to promote their spontaneous metastasis
to bone. Assays mimicking various steps of the metastatic
process suggest a critical role for this receptor in regulating
the chemotactic response of mammary carcinoma cells to
bone-derived factors, in regulating adhesion and migration
towards bone matrix proteins and in the recruitment of osteo-
clasts to bone metastatic sites.
Materials and methods
Cell and cell culture
The mouse mammary epithelial cell lines 4T1, 66cl4 and 67NR
were derived by Dr F Miller (Michigan Cancer Foundation,
Detroit, MI, USA) [42]. 4T1.2 and 4T1.13 are clonal cell lines
derived from 4T1 by our laboratory [40,41]. These cell lines
were cultured in alpha minimal essential medium (α-MEM)
supplemented with 5% FCS and 1% penicillin-streptomycin,
at 37°C, 5% CO2. The ecotropic packaging cell line Phoenix
was a gift from Dr G Nolan (Stanford University, CA, USA) and
was cultured in DMEM supplemented with 10% FCS and anti-
biotics at 37°C, 5% CO2.
The murine microvascular endothelial cell line bEnd.3 was
kindly provided by Dr R Hallman (Jubileum Institute, Sweden)
and was maintained in DMEM supplemented with 10% FCS,
glutamine (2 mM), glucose (4.5 mg/ml) and 1% penicillin-
streptomycin.
Generation and analysis of 66cl4beta3 cells
cDNA encoding full-length mouse β3 integrin (a generous gift
from Dr S Teitelbaum, Washington University, St Louis, MO,
USA) was subcloned into pBabe-puro retroviral vector [43].
Phoenix cells were transiently transfected with target cDNA
and culture supernatant was used to infect 66cl4 cells. Stably
infected cell lines were selected by treatment with 9 µg/ml
puromycin over 7 days. Detection of cell-surface integrin
expression was performed by standard flow cytometry. Briefly,
the cells (1 × 106) were resuspended in blocking buffer (α-
MEM supplemented with 2% BSA and 2% FCS) for 30 min-
utes on ice. The cells were then incubated with 2 µg/ml ham-
ster anti-mouse-αv, anti-β3 or isotype control primary antibody
(BD Pharmingen, North Ryde, NSW, Australia) diluted in labe-
ling buffer (α-MEM supplemented with 2% FCS) for 1 hour on
ice. Unbound antibodies were removed by washing twice with
PBS, 2% FCS, and the cells were treated with a fluorescein
isothiocyanate-conjugated mouse anti-hamster secondary
antibody cocktail (Pharmingen) in labeling buffer for 45 min-
utes on ice, washed as already described and analyzed on a
Calibur fluorescence-activated cell sorter (Becton Dickinson,
North Ryde, NSW, Australia). The brightest 30% of β3-
expressing cells were sorted, expanded in culture and frozen
for all subsequent experiments (66cl4beta3). Fluorescence-
activated cell sorting experiments were completed a minimum
of two times.
Proliferation and adhesion assays
In vitro proliferation assays were performed as described pre-
viously using a sulphorhodamine B colorimetric assay [40].
Proliferation of 66cl4pBabe and 66cl4beta3 cells was meas-
ured over 5 days in complete α-MEM medium with an initial
cell density of 1 × 103/well and five replicate wells/time point.
Adhesion assays were performed in 96-well culture plates as
described previously [44]. Briefly, triplicate wells were pre-
coated overnight at 4°C with BSA (2% w/v), collagen I (20 µg/
ml), collagen IV (20 µg/ml), fibronectin (10 µg/ml), or vitronec-
tin (10 µg/ml). Osteopontin was a gift from Dr L Fisher (John
Hopkins School of Medicine, MD, UAS) and was used at a
concentration of 10 µg/ml. Other extracellular matrix proteins
were obtained from Sigma (St-Louis, MO, USA). The cells
were labeled with calcein (Molecular Probes, Eugene, OR,
USA) and seeded at 2 × 104/100 µl in serum-free α-MEM
supplemented with 0.1% BSA, and the plates were spun at
400 × g for 5 minutes at 4°C. The cells were allowed to adhere
for 30 minutes at 37°C. Nonadherent cells were removed by
gentle washing with PBS and adherent cells were lysed with
1% Triton X-100. Where indicated, function-blocking hamster
anti-mouse  β3 integrin or control antibodies (10 µg/ml;
Pharmingen) were used for pretreatment of the cells for 15
minutes on ice and added together with the cells to the culture
wells. Adhesion was expressed as the percentage of total cell
input by comparing the specific fluorescence in each well with
that of 100 µl initial cell suspension in a Molecular FX fluores-
cence reader (Bio-Rad Laboratories, Regents Park, NSW,
Australia).
For endothelial adhesion assays, bEnd.3 cells were seeded in
complete DMEM medium and incubated overnight to form aBreast Cancer Research    Vol 8 No 2    Sloan et al.
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confluent monolayer. Excess cells and medium were removed
with PBS and calcein-labeled tumor cells (2 × 104/100 µl)
were added in serum-free α-MEM medium supplemented with
0.01% BSA. Culture plates were incubated for 30 minutes at
4°C and for a further 30 minutes at 37°C. Nonadherent tumor
cells were removed and adhesion was measured as described
earlier.
Both the proliferation and adhesion assays were completed a
minimum of three times and the data are presented as the
means ± standard deviation of a representative experiment
performed in three (adhesion) or five (proliferation) replicate
wells. The statistical differences were analyzed using the Stu-
dents' t test; P < 0.01 was considered significant.
Migration and invasion assays
Haptotactic cell migration and invasion were assayed in Tran-
swell migration chambers (8 µm pore size; Corning, Lindfield,
NSW, Australia). For haptotactic migration assays, inserts
were coated on the underside with extracellular matrix mole-
cules overnight at 4°C as described for the adhesion assay.
Cells (2 × 105/100 µl) were seeded into duplicate chambers
and allowed to migrate for 4 hours at 37°C in the absence of
serum. For invasion assays, cells were embedded in 50%
Matrigel/PBS into the upper chamber and were allowed to
invade and migrate toward a serum gradient (5% FCS) in the
bottom well for 24 hours at 37°C. Cells were fixed in 10% buff-
ered formalin, permeabilized in 0.1% Triton-X 100 and stained
with 0.5 µg/ml 4'-6-Diamodino-2-phenylindole (Sigma). Cells
remaining on the upper side of the insert were removed by
wiping with cotton wool and the membrane was mounted on a
glass slide. Cells that had migrated to the underside of the
membrane were counted under fluorescence with 40× magni-
fication and the average number of cells in three microscope
fields/membrane was determined. Function-blocking hamster
anti-mouse β3 integrin or control antibodies were used for pre-
treatment of the cells as described for the adhesion assay. The
matrix metalloproteinase (MMP) inhibitor AG3340 (10 µM;
Agouron Pharmaceuticals, San Diego, CA, USA) or vehicle
alone (dimethyl sulfoxide) were used to pretreat the cells for
48 hours in standard cultures prior to the assay and were
added at the same concentration to the cells in the chamber
wells.
For chemotactic migration, the tibias and femurs were har-
vested from Balb/c mice, crushed and digested for 60 minutes
with a solution of PBS, collagenase type II (6 mg/ml; Gibco,
Mount Waverley, VIC, Australia) and dispase II (8 mg/ml;
Roche Diagnostics, Mannheim, Germany). The cell suspen-
sion was filtered through a 70 µm nylon filter and was washed
three times by centrifugation in PBS. The cell pellet was resus-
pended in α-MEM, 10% FCS and the cells were allowed to
form a confluent monolayer in the bottom well of Transwell
migration chambers. The cells were washed extensively with
PBS, and then 600 µl serum-free α-MEM was added and the
cells were incubated at 37°C for a further 2 hours at 37°C.
Calcein-labeled tumor cells (2 × 105 in serum-free α-MEM)
were pretreated or not with blocking antibodies, added to the
upper well and placed above the bone cell-containing lower
wells. Migration to the underside of the porous membrane was
measured after four hours as described earlier.
All migration and invasion assays were completed at least
three times in duplicate wells. For each duplicate, the number
of migrated cells was counted in three fields of view/mem-
brane for a total of six cell counts/condition. The results from a
representative experiment are shown and expressed as the
mean number of migrated cells/field ± standard deviation of
six fields of view/condition. The statistical differences were
analyzed using the Students' t test; P < 0.01 was considered
significant.
Animal studies
Mice were maintained in a specific pathogen-free environment
with food and water freely available. All procedures involving
mice accorded with National Health and Medical Research
Council animal ethics guidelines. All mice used were female
Balb/c (Animal Resources Centre, Perth, Australia). For intrat-
ibial injections, mice 3–4 weeks old were anesthetized by
intraperitoneal injection of 40 µg ketamine/g mouse and 16 µg
xylazine/g mouse. Cells (1 × 103) in 20 µl PBS were injected
through the proximal tibial metaphysis using a 26 G needle.
Mice received the analgesic carprofen (4 µg/g mouse) at the
time of injection, on the next day, and daily doses from day 10
to day 14. Mice were culled by anesthetic overdose after 14
days. For intramammary fatpad injections, mice 6–8 weeks old
were anesthetized with methoxyfluorane. Cells (1 × 104) in 10
µl PBS + 10 µl Matrigel were injected transdermally into the
fourth (inguinal) mammary fat pad. Mice were culled by anes-
thetic overdose after 39 days. Primary tumors were dissected
and weighed. Lungs and spines were dissected and snap fro-
zen in liquid nitrogen. Femurs were processed for histology as
described in the following.
Analysis of metastatic tumor burden
Real-time quantitative PCR (RTQPCR) using Taqman chemis-
try (PE Biosystems, Foster City, CA, USA) was used to deter-
mine the relative metastatic tumor burden in mouse organs
after injection of tumor cells into the fat pad [40]. Genomic
DNA was extracted from organs and a multiplex reaction was
performed on genomic DNA from each organ to determine the
ratio of the vimentin signal (present in all cells) to the LXSN sig-
nal (retroviral LTR sequence present in stably integrated pBabe
vector in tumor cells only). Primers and probes were designed
using Primer Express (Applied Biosystems, Foster City, CA,
USA), and were as follows (shown 5' to 3' with the correspond-
ing Genbank accession number and the nucleotide positions
of the amplicon): LXSN (GenBank accession number
M28248; nucleotides 1,051–1,162 base pairs): forward,
TGGCCCGACCTGAGGAA; reverse, CAGACGGAGGCG-Available online http://breast-cancer-research.com/content/8/2/R20
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GGAACT; probe, 6FAM-CCCGTCAGGATATGTGGTTCT-
GGTAGGA-TAMRA; Vimentin (GenBank accession number




Multiplex PCR reactions (1 × Taqman Universal PCR Master
Mix, 50 nM vimentin forward and reverse primers, 50 nM
vimentin probe, 150 nM LXSN forward and reverse primers
and 50 nM LXSN probe, approximately 1 ng DNA) were
cycled according to the standard protocol in an ABI PRISM
7000 Sequence Detection System (Applied Biosystems). At
the end of the reaction, a fluorescence threshold was set just
above baseline fluorescence levels, within the range of linear
amplification. The cycle number at which fluorescence for
vimentin and LXSN signals passed the threshold (CT value)
was determined for each sample. The ∆CT value was deter-
mined by subtracting CT(Vim) from CT(LXSN). ∆CT was then used
to calculate the relative tumor burden (RTB) according to the
equation RTB = 2CorrρCt × 1000, where CorrρCt is the ρ Ct
value that includes a correction for the difference in LXSN
copy number between tumor lines as determined by multiplex
RTQPCR on tissue culture cells.
Histology and tartrate-resistant acid phosphatase 
staining
Tissues were dissected and fixed in 10% buffered formalin,
bones were decalcified in ethylenediamine tetraacetic acid
and tissues were embedded in paraffin wax. Tissue sections (4
µm) were stained with H & E for morphology or were assayed
for tartrate-resistant acid phosphatase activity using the Leu-
kocyte Acid Phosphatase kit (Sigma) according to the manu-
facturer's instructions.
Statistical analysis of in vivo data
All data for the measurement of the tumor volume and the
tumor weight and for the RTQPCR analysis of relative tumor
burden were derived from 15 mice/group or 10 mice/group for
intratibial tumor injection. A Kolmogorov–Smirnov normality
test was performed on each group to determine whether the
data within groups show a normal distribution. For data that
passed the normality test, the statistical differences between
groups were analyzed using a Students' t test. Data that failed
the normality test were analyzed for differences between
groups using the Mann–Whitney rank sum test; P ≤ 0.01 was
considered significant.
Figure 1
αvβ3 integrin expression in tumor lines of the metastasis model αvβ3 integrin expression in tumor lines of the metastasis model. Cell surface expression of integrin subunits was determined by measuring the spe-
cific fluorescence by flow cytometry as described in Materials and methods. Shaded area, isotype; dotted line, αv; solid line, β3.Breast Cancer Research    Vol 8 No 2    Sloan et al.
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Results
Expression of αvβ3 integrin in the mammary tumor lines
The orthotopic breast cancer model consists of several cell
lines with well-characterized metastatic profiles [40,41]. The
4T1.2 and 4T1.13 lines are highly metastatic to lymph nodes,
lungs and bone following inoculation into the mammary gland.
The 66cl4 line shows a low level of metastasis from the mam-
mary fat pad to the lung, but not to bone. The 67NR line is non-
metastatic. All four lines were derived from the same
spontaneous mammary carcinoma in a Balb/c/C3H mouse
[42]. Expression of αvβ3 integrin in these cell lines was inves-
tigated by flow cytometry using antibodies specific to the αv
and  β3 subunits and an isotype-matched control antibody.
Both  αv and β3 subunits were expressed by 4T1.2 and
4T1.13 (Figure 1). 67NR and 66cl4 expressed low levels of
the  αv subunit, but not of β3 integrin. The expression of
integrin αvβ3 is therefore restricted to bone metastatic lines in
this model and is correlated with their aggressive metastatic
phenotype.
To investigate the relationship between αvβ3 integrin expres-
sion and bone metastasis, β3 integrin expression was induced
in 66cl4 cells by retroviral infection of mouse β3 cDNA. A pool
of cells stably expressing high levels of β3 was selected by
puromycin resistance followed by fluorescence-activated cell
sorting. These cells were designated 66cl4beta3 and repre-
sent the brightest 30% of the total puromycin-resistant popu-
lation. Expression of β3 integrin enhanced expression of both
Figure 2
Tumor expression of αvβ3 integrin promotes spontaneous metastasis to the spine but not primary tumor growth Tumor expression of αvβ3 integrin promotes spontaneous metastasis to the spine but not primary tumor growth. Cells (1 × 104 in 20 µl of 50% 
Matrigel) were inoculated into the mammary gland of Balb/c mice (15 mice per group). (a) Primary tumor volumes were measured three times per 
week. (b) Primary tumor weights were recorded on the day of harvest (day 39). (c) In vitro proliferation of 66cl4pBabe and 66cl4beta3 cells. The 
tumor burden in the (d) spine and (f) lungs was measured by real-time quantitative PCR as described in Materials and methods. Each point repre-
sents one mouse, but not all points are distinguishable. The average metastatic burden for each group is shown with a line. *P = 0.01. (e) H&E of a 
66cl4beta3 spontaneous femoral metastasis. A metastatic nodule (M) in proximity of a blood vessel (BV) is seen invading through the cortical bone 
(C). Scale bar = 100 µm.Available online http://breast-cancer-research.com/content/8/2/R20
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β3 and αv integrin subunits at the cell surface (Figure 1). The
same phenomenon has been reported in MCF-7 breast cancer
cells following exogenous expression of the β3 subunit [35]
and may be due to enhanced transcription of the αv subunit or
redistribution of a pre-existing intracellular pool. Integrin αvβ3
expression was stable in 66cl4beta3 cells for the duration of
the experiments.
αvβ3 integrin enhances spontaneous metastasis to the 
lung and bone
Given the correlation between αvβ3 expression and the ability
to metastasize to bone in the metastasis model, it was of inter-
est to determine whether expression of this integrin altered the
primary tumor growth or metastasis in Balb/c mice.
66cl4pBabe or 66cl4beta3 cells were injected into the fourth
mammary fat pad of Balb/c mice (n = 15/group). Tumors were
palpable 9 days after injection. The 66cl4beta3 tumors grew
slightly faster than the control group, although the difference
in the growth rate (Figure 2a) or the final tumor weight at the
completion of the experiment on day 39 (Figure 2b) was not
statistically significant. Similarly, there was no difference
between the proliferation rates of 66cl4beta3 and
66cl4pBabe cells in vitro (Figure 2c). The expression of αvβ3
integrin therefore does not alter tumor growth at the primary
site.
Lungs and spines were harvested for analysis of the metastatic
tumor burden by RTQPCR. The metastatic burden of
66cl4beta3 cells in the spine increased 20-fold over that
observed with 66cl4pBabe cells, with a relative tumor burden
of 25.8 ± 9.2 in 66cl4beta3 compared with 1.3 ± 0.4 in
66cl4pBabe (P = 0.01) (Figure 2d). Spines were chosen for
quantitative RTQPCR analysis of the tumor burden in bone
because the metastatic burden in the spine is typically larger
and more frequent in this model than metastasis to the femur
or tibia. Spontaneous metastasis of 66cl4beta3 tumors to long
bones clearly occurred in some mice, however, as evidenced
by histological examination of femoral sections (Figure 2e). As
expected, no femoral metastases were seen in mice injected
with 66cl4pBabe cells.
Similarly, there was a trend toward increased metastasis of
66cl4beta3 tumors to the lung compared with 66cl4pBabe
tumors, with average relative tumor burdens of 590 ± 303 and
295 ± 163 (mean ± standard error of the mean), although the
difference did not reach statistical significance (P = 0.32) –
most probably due to the stochastic nature of spontaneous
metastasis (Figure 2f). It should be noted that the high lung
tumor burden in mice injected with 66cl4beta3 limited the
lifespan of these mice and necessitated early termination of
the experiments, therefore restricting the time available for the
development of bone metastases. Attempts to extend the 39-
day endpoint by resection of the primary tumors at day 14 did
not increase survival time appreciably due to early onset of
lung metastases.
Visual examination of all mice at harvest failed to detect visible
66cl4pBabe or 66cl4beta3 metastases in the lymph nodes,
liver or kidneys (data not shown). Taken together, these results
demonstrate that expression of αvβ3 integrin in breast tumor
Figure 3
Tumor αvβ3 integrin enhances osteoclast recruitment and osteolysis  following intratibial injection of tumor cells Tumor αvβ3 integrin enhances osteoclast recruitment and osteolysis 
following intratibial injection of tumor cells. (a) The relative tumor bur-
den was measured by real-time quantitative PCR 14 days following 
direct intratibial injection of 66cl4pBabe and 66cl4beta3 cells. Repre-
sentative H&E-stained sections through tibias injected with (b) 
66cl4beta3 or (c) 66cl4pBabe cells. Osteoclasts are marked with 
arrows. B, bone; T, tumor. Scale bar = 50 µm. (d) Serial sections adja-
cent to those stained by H&E were stained for tartrate-resistant acid 
phosphatase (TRAP) activity, and the active osteoclasts (TRAP-posi-
tive) present per millimeter of bone in tibias injected with either 
66cl4beta3 or 66cl4pBabe cells were counted. Results of two inde-
pendent experiments are shown. n = 4 mice/group per experiment *P < 
0.001.Breast Cancer Research    Vol 8 No 2    Sloan et al.
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cells induces spontaneous metastasis from the mammary
gland to bone in a tumor line that does not normally metasta-
size to this organ.
Tumor expression of αvβ3 integrin is not required for 
proliferation in bone but enhances osteoclast 
recruitment and osteolysis
To determine whether expression of αvβ3 integrin is required
for proliferation in bone, 66cl4beta3 or 66cl4pBabe cells were
injected directly into the tibia. Mice were culled after 14 days
and the tibias were processed for quantitative measurement of
the tumor burden by RTQPCR or for histological examination
of serial sections taken from three levels through each tibia,
and were stained with H&E to confirm tumor growth and to
measure the length of the bone surface adjacent to the tumor
nodule. As shown in Figure 3a–c, the extent of the tumor
deposit was similar for 66cl4pBabe and 66cl4beta3 cells,
indicating that tumor expression of αvβ3 integrin does not
directly confer a proliferative advantage in bone and that the
failure of 66cl4pBabe to metastasize spontaneously to bone is
not due to its inability to grow in this organ.
Osteoclast-mediated resorption of bone is intimately linked to
growth of breast cancer in bone [45]. Recruitment and activa-
tion of osteoclasts in proximity of the metastatic nodule is well
documented and thought to contribute indirectly to metastatic
growth in bone via the release of mitogenic factors from the
bone matrix [46]. To determine whether expression of αvβ3
alters tumor-associated bone resorption, the ability of
66cl4beta3 cells to influence osteoclastogenesis within the
bone microenvironment following intratibial injection of the
cells was investigated. Sections adjacent to those stained with
H&E were stained for tartrate-resistant acid phosphatase
activity to detect active osteoclasts (Figure 3a,b). The density
of osteoclasts (osteoclasts/mm) was determined at each level
through each tibia. Analysis of tibias injected with 66cl4beta3
and 66cl4pBabe cells in two independent experiments
showed that osteoclast density was approximately twofold
higher in the 66cl4beta3 tibial tumors (Figure 3c). Osteoclasts
were present at the interface between the bone and tumor
cells and also at the interface between the tumor and the bone
marrow. Cortical bone surfaces adjacent to 66cl4beta3 tumor
nodules showed extensive resorption (Figure 3a). In contrast,
fewer osteoclasts and negligible bone resorption were
observed in the proximity of the 66cl4pBabe tumor deposits
(Figure 3b).
Expression of αvβ3 integrin stimulates tumor cell 
adhesion to vitronectin
To explore the mechanisms by which αvβ3 integrin enhanced
metastasis to bone, the ability of the cells to adhere to extra-
cellular matrix molecules was investigated (Figure 4). In this
short-term adhesion assay (30 minutes), none of the lines
adhered to the control BSA coating. The 67NR line adhered
only weakly to vitronectin, fibronectin and collagen IV (Figure
Figure 4
αvβ3 integrin mediates mammary tumor cell adhesion to vitronectin but  not to endothelial cells αvβ3 integrin mediates mammary tumor cell adhesion to vitronectin but 
not to endothelial cells. (a) Short-term adhesion to different matrices. 
(b) Effect of neutralizing antibodies against β3 integrin on short-term 
adhesion to vitronectin. (c) Adhesion of 66cl4pBabe and 66cl4beta3 
cells to a monolayer of bEnd.3 endothelial cells in the absence of 
serum. The experiments were repeated at least twice and the results 
represent the mean ± standard deviation of a representative experiment 
performed in triplicate wells. *P < 0.001.Available online http://breast-cancer-research.com/content/8/2/R20
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4a). None of the substrates tested promoted rapid adhesion of
the weakly metastatic line 66cl4pBabe. Exogenous expres-
sion of αvβ3 integrin in 66cl4 cells, however, resulted in mark-
edly increased adhesion to vitronectin, but not to other
matrices (Figure 4a). Bone metastatic 4T1.2 cells similarly
adhered most avidly to vitronectin but poorly to other sub-
strates, whereas 4T1.13 cells showed moderate binding to
collagen IV and vitronectin (Figure 4a). In adhesion assays
extended over several hours, the cells adhered to all these
matrices (data not shown). Treatment of 66cl4beta3 and
4T1.2 cells with a function-blocking anti-β3 integrin antibody,
but not with an isotype-matched control antibody, substantially
inhibited their adhesion to vitronectin, indicating that adhesion
to vitronectin was mediated specifically via αvβ3 integrin (Fig-
ure 4b). A similar inhibition of binding to vitronectin was
observed in the 4T1.13 line (data not shown).
Additional experiments were conducted to assess whether
tumor αvβ3 may contribute to attachment to endothelial cells,
a process required for intravasation/extravasation of meta-
static tumor cells in vivo. We compared 66cl4pBabe and
66cl4beta3 cells for their ability to attach to a confluent mon-
olayer of microvascular endothelial bEnd.3 cells in the
absence of serum. As shown in Figure 4c, both 66cl4pBabe
and 66cl4beta3 cells adhered to bEnd.3 cells to the same
extent, indicating that αvβ3 is not required for their adhesion
to endothelial cells.
αvβ3 integrin promotes migration and invasion of 66cl4 
cells
To metastasize successfully, cells need to acquire a motile
phenotype and to invade through the basement membrane
and surrounding stroma. Site-specific metastasis has been
proposed to be regulated, in part, by adhesion to and migra-
tion towards the ECM expressed at metastatic sites. To
explore the role of αvβ3 integrin in these processes, we first
compared the haptotactic migration of 66cl4pBabe and
66cl4beta3 cells towards specific extracellular matrix sub-
strates coated on the underside of the porous membranes of
the transwell inserts (Figure 5a). The inserts were placed in
wells containing serum-free medium. Collagen IV stimulated
the haptotactic migration of 66cl4pBabe cells with a further
enhancement in 66cl4beta3 cells. This migration, however,
was not blocked by antibodies targeting β3 integrin (Figure
5a). Control 66cl4pBabe cells showed no haptotactic migra-
tion towards osteopontin, an abundant αvβ3 integrin ligand in
bone, presumably due to their lack of αvβ3 expression. Con-
sistent with this, 66cl4beta3 cells were strongly migratory
towards osteopontin in a process blocked completely by neu-
tralizing antibodies against integrin β3. Migration towards vit-
ronectin was also strongly stimulated by β3 integrin
expression in 66cl4beta3 cells and was partially inhibited by
neutralization of αvβ3 (Figure 5a).
Figure 5
Expression of αvβ3 integrin promotes tumor cell migration and invasion Expression of αvβ3 integrin promotes tumor cell migration and invasion. 
Migration and Matrigel invasion assays were performed in Transwell 
migration chambers (8 µm pore size). (a) Haptotactic migration in 
response to collagen IV, osteopontin and vitronectin and the effect of 
neutralizing β3 antibodies. (b) Effect of the matrix metalloproteinase 
inhibitor AG3340 (10 µM) on the haptotactic migration of 4T1.2 and 
66cl4beta3 cells. (c) Chemotactic migration of 66cl4pBabe and 
66cl4beta3 cells towards a monolayer of bone stromal cells seeded in 
the lower chamber. (d) Invasion of cells through Matrigel in response to 
a serum chemotactic gradient. All assays were performed in duplicate 
wells and the cells counted from three fields of view/membrane at 40× 
magnification (a, b and d) or 20× magnification (c). The experiments 
were repeated at least twice and the data represent the mean number 
of migrated cells ± standard deviation of six fields of view/condition 
from a representative experiment performed in duplicate wells. *P < 
0.01, **P < 0.001.Breast Cancer Research    Vol 8 No 2    Sloan et al.
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The cooperative role of integrins and MMPs in tumor cell
migration and invasion has been extensively documented. We
have previously reported that all of the tumor lines of the model
express similar levels of MT1-MMP but none express detecta-
ble MMP-2. The bone metastatic 4T1.2 cells express signifi-
cantly higher levels of MMP-9 than 66cl4 or 67NR cells [47].
We confirmed here by gelatin zymography that exogenous
expression of αvβ3 integrin in 66cl4 cells did not induce MMP-
2 or alter the profile of MMP-9 expression when the cells were
plated on plastic or on vitronectin (data not shown), suggest-
ing that increased haptotactic migration of 66cl4beta3 cells
towards vitronectin occurred independent of changes in
MMP-2 and MMP-9 expression levels.
To determine whether protease activity is required for vitronec-
tin-mediated haptotactic migration of 4T1.2 and 66cl4beta3
cells, we tested the effect of the broad-spectrum hydroxamate
MMP inhibitor Prinomastat (AG3340) in the haptotaxis assay.
For these experiments, the cells were pretreated with low
doses of AG3340 (10 µM) for 48 hours prior to seeding into
uncoated or vitronectin-coated wells. At this concentration, no
toxicity was observed in vehicle (dimethyl sulfoxide)-treated
cells or AG3340-treated cells. As seen earlier, neither 4T1.2
nor 66cl4beta3 migrated in the absence of coated substrate
but their migration was strongly induced by the presence of vit-
ronectin (Figure 5b). Importantly, pretreatment with AG3340
inhibited 4T1.2 and 66cl4beta3 cell migration by 23% and
40% respectively, compared with control dimethyl sulfoxide
alone. αvβ3 integrin-mediated migration of bone metastatic
mammary carcinoma cells towards vitronectin is therefore
dependent, in part, on extracellular protease activity.
To determine whether secreted factors produced in the bone
microenvironment may also contribute to homing of
66cl4beta3 cells to bone, we compared the effect of bone
stromal cells isolated from tibias and femurs of Balb/c mice on
the chemotactic migration of 66cl4pBabe and 66cl4beta3
cells in the absence of serum. As shown in Figure 5c, neither
line migrated in the absence of bone cells in the bottom cham-
ber. In contrast, while chemotactic migration of 66cl4pBabe
was negligible when stromal cells were added to the lower
chamber, 66cl4beta3 efficiently migrated under these condi-
tions. Importantly, chemotactic migration of 66cl4beta3 cells
was almost completely abrogated by treatment with β3-neu-
tralizing antibodies but not by control antibodies (Figure 5c).
The invasive capacity of 66cl4pBabe and 66cl4beta3 cells
was assessed by their ability to move through a Matrigel bar-
rier in response to a chemotactic gradient provided by FCS in
the lower chamber. The αvβ3 integrin-expressing 66cl4beta3
cells showed enhanced invasion through Matrigel compared
with 66cl4pBabe (Figure 5d).
Taken together, these results demonstrate that expression of
αvβ3 integrin promotes mammary carcinoma cell adhesion to
and haptotactic migration towards bone matrix proteins,
enhances their responsiveness to bone-derived soluble factor
and increases their invasive properties. Migration towards vit-
ronectin appears to be partially dependent on MMP activity.
Discussion
Numerous in vitro and in vivo studies have documented the
correlation between tumor expression of αvβ3 integrin and the
bone metastatic potential of breast tumors and other human
tumors [7,25,26,48-50]. Our observation that only aggressive
and bone metastatic mammary carcinoma cell lines of our
murine model express this receptor is consistent with these
studies. The precise role of tumor-specific αvβ3 integrin and
its relative contribution to primary tumor growth and bone
metastasis remains unclear. This is due in part to the lack of
clinically relevant syngeneic models of spontaneous breast
cancer metastasis that recapitulate the entire metastatic cas-
cade from the mammary gland to bone. We report in the
present article that exogenous expression of αvβ3 integrin in
mammary carcinoma cells that do not normally metastasize to
bone is sufficient to promote their spontaneous metastasis to
this organ. To our knowledge, these data provide the first
direct in vivo evidence that tumor αvβ3 integrin contributes to
the spontaneous metastasis of breast tumors from the mam-
mary gland to bone.
Increased bone metastasis occurred without apparent effect
on 66cl4beta3 primary tumor growth in vivo or proliferation in
vitro. These observations contrast with some [11,20], but not
all [37], studies in xenograft models showing inhibition of
mammary tumor growth by αvβ3 antagonists. Reduced angio-
genesis observed in these tumors suggests that αvβ3 inhibi-
tors impair tumor growth primarily by targeting the tumor
neovasculature rather than the tumor cells. Unlike these stud-
ies, our approach addressed specifically the role of tumor
αvβ3. Comparable growth of 66cl4pBabe and 66cl4beta3
tumors indicates that tumor αvβ3 is unlikely to promote spon-
taneous bone metastasis through stimulation of tumor cell pro-
liferation at the primary site. Instead, results from in vitro
assays suggest that tumor αvβ3 may have multiple roles
downstream of primary tumor growth that contribute to
enhanced metastasis to bone. This conclusion is supported by
the observation that the selective αvβ3 antagonist S247 inhib-
its the metastasis of αvβ3-expressing MDA-MB-435 to bone
in the experimental metastasis model that bypasses the forma-
tion of a primary tumor [39].
While our results show increased spontaneous metastasis
predominantly to bone and are consistent with data from
experimental models, they do not preclude that tumor αvβ3
may enhance metastasis to several organs in part through its
effect on earlier stages of metastasis, such as escape from the
primary tumor and intravasation. For instance, we found that
66cl4beta3 cell migration towards collagen IV and invasion
through Matrigel were substantially increased compared with
that of 66cl4pBabe cells (see Figure 5a). Both theseAvailable online http://breast-cancer-research.com/content/8/2/R20
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responses are likely to be important in early dissemination of
metastatic cells from the mammary gland and may explain also
the trend towards increased spontaneous metastasis to lung
observed in our model (Figure 2e). This would be consistent
also with the inhibitory effect of S247 reported on the sponta-
neous metastasis of MDA-MB-435 cells to the lung despite its
lack of effect on primary tumor growth in the mammary gland
[37].
The mechanisms leading to increased collagen-IV-mediated
migration of 66cl4beta3 cells are unclear but could involve
MT1-MMP-dependent regulation of cross-talk between αvβ3
integrin and the α2β1 collagen receptor, as reported previ-
ously in human breast carcinoma cells [51]. In particular, these
authors noted that MCF-7 cells expressing both MT1-MMP
and αvβ3 integrin were more migratory towards collagen I than
MCF-7 cells expressing only MT1-MMP. By analogy,
66cl4beta3 cells express both αvβ3 and MT1-MMP whereas
66cl4pBabe express only MT1-MMP ([47] and this study).
In agreement with previous reports [25-27,30,38], we found
that expression of αvβ3 integrin in 66cl4beta3 cells dramati-
cally enhanced their αvβ3-dependent adhesion and haptotac-
tic migration towards bone matrix proteins. It is probable that
these interactions are critical for homing of breast tumor cells
to bone. Migration towards vitronectin was partially inhibited
by the MMP inhibitor AG3340, suggesting cooperation
between αvβ3 and MMPs to promote haptotactic migration.
Functional cooperation between αvβ3 integrin and several
MMPs, including MMP-2, MMP-9 and MT1-MMP, has been
demonstrated previously [5,29,31,52]. 66cl4 cells express
similar levels of MT1-MMP but significantly less MMP-9 than
the bone metastatic 4T1.2 cells [47]. Neither line expresses
detectable levels of MMP-2. Since we did not detect any sig-
nificant changes in the levels of MMP-2 or MMP-9 activity
between 66cl4beta3 and 66cl4pBabe cells by gelatin zymog-
raphy, cooperation between αvβ3 and MMP-2/9 is unlikely to
account for the enhanced haptotactic response observed in
66cl4beta3 cells.
Interestingly, Deryugina and colleagues reported that expres-
sion of αvβ3 in MCF-7 cells is insufficient alone to promote
their migration towards vitronectin and requires the proteolytic
processing of the αvβ3 receptor by MT1-MMP to migrate
[29,53]. Short-term treatment of MCF-7 cells coexpressing
MT1-MMP and αvβ3 with AG3340 blocked direct proteolysis
of vitronectin by MT1-MMP and enhanced migration. In con-
trast, due to the slow turnover of αvβ3, long-term treatment
was required to replace existing pools of αvβ3 proteolytically
activated by MT1-MMP at the cell surface and to inhibit migra-
tion. Similarly, long-term treatment (48 hours) with AG3340
was required to block 4T1.2 and 66cl4beta3 cell migration
(see Figure 5b). Although we cannot completely rule out a
potential interaction between αvβ3 and MMP-9 in 66cl4beta3
cells, these observations suggest that functional activation of
αvβ3 by MT1-MMP may be more relevant to the haptotactic
response of 66cl4beta3 cells to vitronectin.
While our results clearly implicate tumor αvβ3 in breast cancer
metastasis to bone, it should be noted that the metastatic bur-
den observed with 66cl4beta3 was not as high as that typi-
cally seen using the more aggressive 4T1.2 and 4T1.3 lines
[40]. There therefore does not appear to be a direct correla-
tion between the level of αvβ3 expression and the extent of
metastasis to bone. Presumably, the level of αvβ3 integrin
found in 4T1.2/4T1.13 cells is sufficient to promote metasta-
sis to bone, and expression above this level (as seen in
66cl4beta3) does not offer additional benefits. Moreover,
unlike 4T1.2/4T1.13 lines, we failed to detect any spontane-
ous 66cl4beta3 metastases in the lymph nodes, kidney or
liver. A probable explanation for these differences is that other
factors not present in 66cl4beta3 cells cooperate with αvβ3
integrin and contribute to the high metastatic phenotype of
4T1.2/4T1.13 lines. Although we found no evidence implicat-
ing MMP-9 in the 66cl4beta3 migratory response to vitronec-
tin, it is tempting to speculate that enhancing the level of MMP-
9 expression (as seen in 4T1.2 and 4T1.13 cells) together with
expression of αvβ3 in 66cl4beta3 cells may be sufficient to
achieve the high metastatic burden observed with 4T1.2 and
4T1.13 tumors. Alternatively, coexpression of αvβ3 and its
ECM ligand may be required to further enhance the
66cl4beta3 metastatic potential as demonstrated in 21NT
human xenografts [34]. Consistent with this, cDNA microarray
analysis of primary tumors of our model revealed that several
ECM-related genes are more highly expressed in bone meta-
static lines (4T1.2, 4T1.13) compared with weakly metastatic
(66cl4) and nonmetastatic (67NR) lines [40]. The cooperative
role of some of these ECMs and αvβ3 integrin is under inves-
tigation.
Tumor αvβ3 has been proposed to enhance metastasis by
facilitating tumor cell arrest in the vasculature through interac-
tion with platelets and adhesion to the subendothelial matrix
[14,32]. 66cl4pBabe and 66cl4beta3 cells adhered equally
well to endothelial cells, indicating that receptors other than
αvβ3 integrin mediate their attachment to the endothelium
under our assay conditions. It should be noted, however, that
the assays were conducted in the absence of serum and thus
a role for αvβ3-mediated tumor–platelet interaction under
blood flow conditions cannot be ruled out. Further work will be
required to address this possibility.
Exogenous expression of αvβ3 integrin dramatically enhanced
the chemotactic migration of 66cl4beta3 cells towards solu-
ble factors secreted by bone stromal cells. Almost complete
inhibition of chemotaxis by β3-blocking antibodies indicates
that the antibody either prevents binding of αvβ3 receptor to a
soluble ECM ligand and/or interferes with the association of
αvβ3 and a chemotactic receptor. Several factors produced in
the bone stromal microenvironment have been shown to pro-Breast Cancer Research    Vol 8 No 2    Sloan et al.
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mote chemotactic migration, including insulin-like growth fac-
tors, platelet-derived growth factor (PDGF) and stromal cell
derived factor 1 (sdf-1/CXCL12) [45,54-56]. While we have
yet to determine the specific bone stromal factor stimulating
the 66cl4beta3 cell chemotactic response, PDGF may be of
particular interest as αvβ3 integrin has been shown to associ-
ate with the PDGF receptor β and to enhance chemotactic
migration in response to PDGF stimulation [57-59]. Moreover,
PDGF is a potent mitogen for breast tumor cells and blocking
PDGF receptor signaling in these cells inhibits their growth in
bone and associated osteolysis [60].
The observations that 66cl4pBabe tumors were able to grow
when injected directly into the tibia clearly demonstrate that
tumor αvβ3 is not required for proliferation of breast tumor
cells in bone. Moreover, the fact that they proliferated to the
same extent as 66cl4beta3 tumors despite evidence of osteo-
clast recruitment or large lytic lesions indicates that extensive
bone degradation is not required for metastatic growth to
occur in bone. The increased recruitment of osteoclasts in the
proximity of 66cl4beta3 tumor nodules and evidence of oste-
olysis at the tumor–bone interface, however, are consistent
with the vicious cycle theory, and suggesting that tumor αvβ3
may play an indirect role in promoting the growth of breast
cancer cells that spontaneously metastasize to bone through
enhanced osteoclast-mediated bone resorption and release of
mitogenic factors from the bone matrix [46]. Engagement of
αvβ3 integrin with bone ECM proteins may induce production
of an osteoclast-stimulating factor, such as RANKL or colony
stimulating factor 1, by tumor cells or by bone marrow cells.
Alternatively, tumor αvβ3 may promote osteoclastogenesis
through interaction with activated platelets in the bone micro-
environment [61]. While Boucharaba and colleagues did not
specifically investigate the role of tumor αvβ3, they showed
that interaction of human MDA-MB-231/B02 breast tumor
cells with platelets promotes osteoclast-mediated bone
resorption through the release of cytokines (IL-6 and IL-8) in
response to platelet-derived lysophosphatidic acid. Further
work will be required to elucidate the mechanism by which
tumor αvβ3 enhances osteoclastogenesis. Assays that meas-
ure the production of such factors in cocultures of breast can-
cer cells and bone marrow stromal cells may help to elucidate
the mechanism by which tumor αvβ3 integrin promotes the
formation of osteolytic lesions.
Conclusion
We have shown for the first time that tumor αvβ3 integrin con-
tributes to the spontaneous metastasis of breast tumors to
bone. Results from our investigation highlight the critical role
of this integrin in homing of breast tumor cells to bone through
enhanced chemotactic migration and haptotactic migration as
well as in recruiting activated osteoclasts at metastatic
lesions. The addition of an inhibitor specifically targeting tumor
αvβ3 to existing treatments may provide greater therapeutic
benefits for the treatment of patients with advanced breast
cancer.
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